Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia;...
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers.
Target Price
The average target price of ALCLS.PA is 6.5 and suggests 86% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
Buy
Sell